Wei-Wu He and Tak Mak join EntreMed board

EntreMed, a clinical-stage pharmaceutical company developing cancer therapeutics, has appointed Dr Wei-Wu He executive chair, and Dr Tak Mak a member of the board of directors. Dr He is currently CEO and chair of OriGene Technologies, and is the founder and general partner of Emerging Technology Partners. Dr Mak is director of the Campbell Family Institute for Breast Cancer Research at the Princess Margaret Hospital and a professor in the departments of medical biophysics and immunology at the University of Toronto. He is also an officer of the Order of Canada, and a foreign associate of the National Academy of Sciences. He is best known as the leading scientist of the group that first cloned the genes of the human T cell antigen receptor.